Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 210 results:
Συντάκτης [ Τίτλος(Asc)] Τύπος Έτος
Φίλτρα: Συντάκτης is Athyros, Vasilios G  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
P
Doumas, M., Imprialos K. P., Stavropoulos K., & Athyros V. G. (2018).  Peripheral arterial stiffness as a surrogate of central hemodynamics: A new era for cardiovascular risk estimation?. J Clin Hypertens (Greenwich). 20(3), 469-471.
Kakafika, A. I., Mikhailidis D. P., Wierzbicki A. S., Karagiannis A., & Athyros V. G. (2007).  PCI and stable coronary heart disease--COURAGE to change our minds?. Curr Vasc Pharmacol. 5(3), 173-4.
O
Tziomalos, K., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2008).  Omega-3 fatty acids: how can they be used in secondary prevention?. Curr Atheroscler Rep. 10(6), 510-7.
Athyros, V. G., Katsiki N., & Karagiannis A. (2016).  Off target effects of statins shape total mortality?. J Drug Assess. 5(1), 4-5.
N
Athyros, V. G., Tziomalos K., Katsiki N., & Mikhailidis D. P. (2014).  Novel data on the pathogenesis of atherosclerosis, treatment targets, and new therapeutic interventions in lipid-related cardiovascular risk factors.. Curr Pharm Des. 20(40), 6215-9.
Athyros, V. G., Polyzos S. A., Kountouras J., Katsiki N., Anagnostis P., Doumas M., et al. (2019).  Non-alcoholic fatty liver disease treatment in patients with type 2 diabetes mellitus; new kids on the block.. Curr Vasc Pharmacol.
Tziomalos, K., Athyros V. G., Paschos P., & Karagiannis A. (2015).  Nonalcoholic fatty liver disease and statins.. Metabolism. 64(10), 1215-23.
Athyros, V. G., Katsiki N., & Karagiannis A. (2013).  Nonalcoholic fatty liver disease and severity of cardiovascular disease manifestations.. Angiology. 64(8), 572-5.
M
Mitsiou, E. K., Tziomalos K., Anagnostis P., Karagiannis A., & Athyros V. G. (2009).  Multifactorial intervention for the prevention of vascular complications of type 2 diabetes.. Hellenic J Cardiol. 50(6), 445-8.
Athyros, V. G., Papageorgiou A., Athyrou V., & Karagiannis A. (2017).  Mortality reduction in patients treated with intensive lipid therapy vs usual care. Re: Zhao XQ, Phan BA, Davis J et al. Mortality reduction in patients treated with long-term intensive lipid therapy: 25-year follow-up of the Familial Atherosclerosis Tre. J Clin Lipidol. 11(1), 306-307.
Katsiki, N., Athyros V. G., & Karagiannis A. (2014).  Metabolic syndrome in clinical practice.. Cardiol J. 21(2), 209.
Katsiki, N., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2014).  Metabolic syndrome and non-cardiac vascular diseases: an update from human studies.. Curr Pharm Des. 20(31), 4944-52.
Koumaras, C., Katsiki N., Athyros V. G., & Karagiannis A. (2013).  Metabolic syndrome and arterial stiffness: the past, the present and the future.. J Cardiovasc Med (Hagerstown). 14(10), 687-9.
Karagiannis, A., Tziomalos K., Kakafika A. I., Athyros V. G., Harsoulis F., & Mikhailidis D. P. (2008).  Medical treatment as an alternative to adrenalectomy in patients with aldosterone-producing adenomas.. Endocr Relat Cancer. 15(3), 693-700.
Kostapanos, M. S., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2012).  Mechanisms linking nonalcoholic fatty liver disease with coronary artery disease.. Dig Dis Sci. 57(4), 1109.
Katsiki, N., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2012).  Managing the combination of non-alcoholic fatty liver disease and metabolic syndrome.. Expert Opin Pharmacother. 13(2), 287-8; author reply 289-90.
Tziomalos, K., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2010).  Management of statin-intolerant high-risk patients.. Curr Vasc Pharmacol. 8(5), 632-7.
L
Tessier, C. M., Polyzos S. A., Athyros V. G., & Mantzoros C. S. (2021).  Long-term statin treatment for hepatic fibrosis in patients with nonalcoholic fatty liver disease: Is it time to give the emperor a statin robe?. Metabolism. 121, 154796.
Theocharidou, E., Tellis C. C., Mavroudi M., Soufleris K., Gossios T. D., Giouleme O., et al. (2014).  Lipoprotein-associated phospholipase A2 and arterial stiffness evaluation in patients with inflammatory bowel diseases.. J Crohns Colitis. 8(9), 936-44.
Tziomalos, K., Athyros V. G., Wierzbicki A. S., & Mikhailidis D. P. (2009).  Lipoprotein a: where are we now?. Curr Opin Cardiol. 24(4), 351-7.
Athyros, V. G., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2010).  Lipid-lowering agents and new onset diabetes mellitus.. Expert Opin Pharmacother. 11(12), 1965-70.
Tziomalos, K., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2012).  Lipid lowering agents and the endothelium: an update after 4 years.. Curr Vasc Pharmacol. 10(1), 33-41.
Didangelos, T. P., Arsos G. A., Karamitsos D. T., Athyros V. G., & Karatzas N. D. (2003).  Left ventricular systolic and diastolic function in normotensive type 1 diabetic patients with or without autonomic neuropathy: a radionuclide ventriculography study.. Diabetes Care. 26(7), 1955-60.
J
Athyros, V. G., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2009).  The JUPITER trial results boost the evidence for the use of hsCRP as a treatment target and as part of the assessment of vascular risk: time for new guidelines?. Hellenic J Cardiol. 50(2), 89-91.
Tziomalos, K., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2009).  JUPITER: major implications for vascular risk assessment.. Curr Med Res Opin. 25(1), 133-7.

Σελίδες

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.

           

Σύνδεσμοι

 

Το πανεπιστήμιο

 
 

Προσωπικό & Φοιτητές